Search results for "ABO"

showing 10 items of 13628 documents

Congenital secondary hypothyroidism caused by exon skipping due to a homozygous donor splice site mutation in the TSHbeta-subunit gene.

2002

Isolated TSH deficiency as a cause for congenital hypothyroidism is relatively uncommon. Even more rare is the identification of mutations in the TSHβ gene, only four of which have been identified. We here report a 4-month-old girl with isolated TSH deficiency born to consanguineous parents. Sequencing of the TSHβ-subunit gene revealed a homozygous G to A transition at position +5 of the donor splice site of intron 2. TSHβ gene transcript could not be obtained from fibroblasts or white blood cells by illegitimate amplification. Thus, to investigate further the mechanism leading to TSH deficiency in this patient, we used an in vitro exon-trapping system. The mutation at position +5 of the do…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryThyrotropinBiologymedicine.disease_causeBiochemistryExonConsanguinityEndocrinologyInternal medicinemedicineCongenital HypothyroidismMissense mutationHumansspliceRNA MessengerGeneGeneticsMutationSplice site mutationBiochemistry (medical)IntronInfantExonsExon skippingEndocrinologyMutationFemaleRNA Splice SitesThe Journal of clinical endocrinology and metabolism
researchProduct

Can stress biomarkers predict preterm birth in women with threatened preterm labor?

2017

Background: Preterm birth is a major paediatric challenge difficult to prevent and with major adverse outcomes. Prenatal stress plays an important role on preterm birth; however, there are few stress-related models to predict preterm birth in women with Threatened Preterm Labor (TPL). Objective: The aim of this work is to study the influence of stress biomarkers on time until birth in TPL women. Methods: Eligible participants were pregnant women between 24 and 31 gestational weeks admitted to the hospital with TPL diagnosis (n = 166). Stress-related biomarkers (a-amylase and cortisol) were determined in saliva samples after TPL diagnosis. Participants were followed-up until labor. A paramet…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismCortisol03 medical and health sciencesThreatened preterm labor0302 clinical medicineEndocrinologymedicineProspective cohort studyBiological PsychiatrySurvival analysisPregnancy030219 obstetrics & reproductive medicineEndocrine and Autonomic SystemsObstetricsbusiness.industryCase-control studyGestational agealpha-amylaseNomogrammedicine.diseasePsychiatry and Mental healthPremature birthGestationbusiness030217 neurology & neurosurgerySurvival modelPsychoneuroendocrinology
researchProduct

A 15-Year Perspective of the Fabry Outcome Survey

2016

Abstract The Fabry Outcome Survey (FOS) is an international long-term observational registry sponsored by Shire for patients diagnosed with Fabry disease who are receiving or are candidates for therapy with agalsidase alfa (agalα). Established in 2001, FOS provides long-term data on agalα safety/efficacy and collects data on the natural history of Fabry disease, with the aim of improving clinical management. The FOS publications have helped establish prognostic and severity scores, defined the incidence of specific disease variants and implications for clinical management, described clinical manifestations in special populations, confirmed the high prevalence of cardiac morbidity, and demon…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologyoutcomesFabry Outcome Survey03 medical and health sciences0302 clinical medicineInternal medicinemedicineGenetics (clinical)lcsh:R5-920agalsidase alfaFabry diseasebusiness.industryIncidence (epidemiology)Therapeutic effectEnzyme replacement therapymedicine.diseaseFabry diseaseNatural historyPediatrics Perinatology and Child HealthPhysical therapyObservational studybusinesslcsh:Medicine (General)Agalsidase alfa030217 neurology & neurosurgeryenzyme replacement therapy
researchProduct

Developmental programming of energy balance and its hypothalamic regulation.

2011

Developmental programming is an important physiological process that allows different phenotypes to originate from a single genotype. Through plasticity in early life, the developing organism can adopt a phenotype (within the limits of its genetic background) that is best suited to its expected environment. In humans, together with the relative irreversibility of the phenomenon, the low predictive value of the fetal environment for later conditions in affluent countries makes it a potential contributor to the obesity epidemic of recent decades. Here, we review the current evidence for developmental programming of energy balance. For a proper understanding of the subject, knowledge about ene…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismEnergy balanceHypothalamusBiologyPredictive valueRatsFetal DevelopmentMiceEndocrinologyEndocrinologyRisk analysis (engineering)PregnancyInternal medicinePrenatal Exposure Delayed EffectsModels AnimalmedicineAnimalsHumansFemaleEnergy MetabolismDevelopmental programmingOrganismSignal TransductionEndocrine reviews
researchProduct

Anthropometric parameters and permanent remission of comorbidities 10 years after open gastric bypass in a cohort with high prevalence of super-obesi…

2017

Abstract Background and aim Roux-en-Y gastric bypass (RYGB) is an effective treatment for weight loss in patients with morbid obesity. However, few studies have assessed its long-term efficacy in super-obese patients. The study objective was to analyse the long-term effectiveness of RYGB and its effect on improvement of comorbidities after 10 years of follow-up, and to compare the results depending on baseline BMI ( 2 vs ≥50 kg/m 2 ). Patients and methods A retrospective study was conducted in 63 patients referred for RYGB with a 10-year or longer follow-up period. Mean BMI before surgery was 55 kg/m 2 . Results Mean BMI decreased to 38.1 kg/m 2 at 10 years of follow-up. The success rates a…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismGastric bypassGastric Bypass030209 endocrinology & metabolismComorbidityBody Mass Index03 medical and health sciencesPostoperative Complications0302 clinical medicineEndocrinologyWeight lossDiabetes mellitusInternal medicineWeight LossPrevalencemedicinePostoperative Period030212 general & internal medicineDyslipidemiasSleep Apnea ObstructiveNutrition and Dieteticsbusiness.industryRemission Inductionnutritional and metabolic diseasesSleep apneaRetrospective cohort studymedicine.diseaseComorbidityObesity MorbidSurgeryTreatment OutcomeDiabetes Mellitus Type 2SpainHypertensionCohortmedicine.symptombusinessDyslipidemiaFollow-Up StudiesEndocrinología, Diabetes y Nutrición
researchProduct

Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2

2008

Aims/hypothesis Islet autoantibodies are important in diabetes classification and risk assessment, and as endpoints in observational studies. The Diabetes Autoantibody Standardization Program (DASP) aims to improve and standardise measurement of autoantibodies associated with type 1 diabetes. We report results for glutamic acid decarboxylase autoantibodies (GADA) and islet antigen-2 autoantibodies (IA-2A) from three DASP workshops (2002–2005). Methods Up to 60 laboratories in 18 countries participated in each workshop. Participants received coded serum aliquots from 50 patients with newly diagnosed type 1 diabetes (median age 18 years, range 9–35 years) and 100 blood donor controls. Results…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismGlutamate decarboxylaseThe Environmental Determinants of Diabetes in the YoungGastroenterologySensitivity and SpecificityAntigenInterquartile rangeDiabetes mellitusInternal medicineInternal MedicinemedicineDiabetes MellitusHumansReceptor-Like Protein Tyrosine Phosphatases Class 8AutoantibodiesType 1 diabetesReceiver operating characteristicbusiness.industryGlutamate DecarboxylaseAutoantibodymedicine.diseaseAdjusted sensitivity AUC GAD autoantibodies IA-2 autoantibodies Islet autoantibodies Prediction Sensitivity SpecificityROC CurveImmunologybusiness
researchProduct

Insulin Resistance and the Cardiometabolic Syndrome in HIV Infection

2009

Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of HIV-positive patients. However, long-term adverse effects of this therapy include dyslipidemia, insulin resistance (IR), changes in body fat distribution (lipodystrophy), and cardiometabolic syndrome (CMS). IR in HIV-positive patients does not seem to represent a significant independent risk factor for the development of cardiovascular disease; nevertheless, the association with other metabolic complications (dyslipidemia, fat redistribution) and CMS may increase the risk of type 2 diabetes and cardiovascular disease. The use of nucleoside analogue reverse transcriptase inhibitors is associated with the …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHIV InfectionsType 2 diabetesGastroenterologyInsulin resistanceAntiretroviral Therapy Highly ActiveDiabetes mellitusInternal medicineInternal MedicinemedicineHumansRisk factorMetabolic Syndromebusiness.industrymedicine.diseaseMetforminEndocrinologyCardiovascular DiseasesInsulin ResistanceLipodystrophyCardiology and Cardiovascular MedicinebusinessRosiglitazoneDyslipidemiamedicine.drugJournal of the CardioMetabolic Syndrome
researchProduct

Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C

2021

INTRODUCTION: In the last years the Hepatitis C virus (HCV) infection was a relevant public health problem due to the large number of affected people worldwide and the impact on hepatic and extrahepatic complications. The availability of direct-acting antivirals (DAAs) and the very high rate of sustained virological response (SVR) after treatment has radically changed the course of HCV chronic infection. EVIDENCE ACQUISITION: We searched PubMed for articles published between January 1, 1995, through December 31, 2020, in English language. EVIDENCE SYNTHESIS: Robust evidence showed a close link between HCV infection and development of cardiovascular disease (CVD), as result of the atherogeni…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHepatitis C virusMEDLINEHepacivirusDiseaseDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsVirusInternal medicineInternal MedicinemedicineHumansHepatitis chronic Cardiovascular diseases Antiviral agentsIn patientbusiness.industryPublic healthGastroenterologyvirus diseasesHepatitis C Chronicdigestive system diseasesChronic infectionCardiovascular DiseasesPersistent Infectionbusiness
researchProduct

Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity

2004

OBJECTIVE: We investigated the possible causes of diabetes in a young child who presented with hyperglycemia associated with severe hypertriglyceridemia (>166 mmol/l), hypercholesterolemia (>38 mmol/l) and fasting chilomicrons. RESULTS: The patient did not have any of the HLA and autoantibody markers typically associated with type 1 diabetes. A glucose clamp failed to demonstrate insulin resistance (peripheral glucose utilization rate (M)=4.3 mg/kg per min) and there was no family history of type 2 diabetes or maturity onset diabetes in youth. Both fasting and stimulated C-peptide levels, including those in response to i.v. glucagon, were below the limit of detection. This is consiste…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaAutoimmunityType 2 diabeteschylomicronemia diabetes young girl autoimmunityGlucagonIslets of LangerhansLipoprotein lipase deficiencyEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusChylomicronsmedicineHumansChildAutoantibodiesHypertriglyceridemiaType 1 diabetesC-Peptidebusiness.industryHypertriglyceridemiaFastingGeneral MedicineGlucose clamp techniqueGlucagonmedicine.diseaseLipoprotein LipaseDiabetes Mellitus Type 1EndocrinologyHyperglycemiaGlucose Clamp TechniqueFemalelipids (amino acids peptides and proteins)businessEuropean Journal of Endocrinology
researchProduct

Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies

2019

Background: Age, smoking, hypercholesterolemia, and hypertension are major risk factors for atherosclerotic cardiovascular disease. Objective: We examined whether the effects of alirocumab on low-density lipoprotein cholesterol (LDL-C) differed according to age, hypertension, or smoking status. Methods: Data were pooled from 10 Phase 3 ODYSSEY randomized trials (24–104 weeks’ duration) in 4983 people with heterozygous familial hypercholesterolemia (FH) or non–familial hypercholesterolemia (3188 on alirocumab, 1795 on control [620 on ezetimibe and 1175 on placebo]). Most participants received concomitant maximum tolerated statin therapy. In 8 trials, the alirocumab dose was increased from 75…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedPlacebolaw.inventionPCSK903 medical and health sciencesAge0302 clinical medicineRandomized controlled trialEzetimibeRisk FactorslawInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineAdverse effectAgedAlirocumabNutrition and Dieteticsbusiness.industryPCSK9SmokingAge FactorsCholesterol LDLMiddle Agedmedicine.diseaseCholesterolTreatment OutcomeConcomitantHypertensionCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Clinical Lipidology
researchProduct